PLx Pharma Winddown Corp.

2020 Q1 Form 10-Q Financial Statement

#000143774920010864 Filed on May 15, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1 2018 Q4

Balance Sheet

Concept 2020 Q1 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.290M $24.32M $14.25M
YoY Change -61.8% 19.1% -41.6%
Cash & Equivalents $9.287M $24.32M $14.25M
Short-Term Investments
Other Short-Term Assets $250.0K $440.0K $600.0K
YoY Change -43.18% -69.44% -41.18%
Inventory $0.00 $0.00
Prepaid Expenses $409.4K
Receivables $0.00 $20.00K $20.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.581M $24.77M $14.87M
YoY Change -61.32% 12.93% -42.14%
LONG-TERM ASSETS
Property, Plant & Equipment $1.437M $1.346M $1.394M
YoY Change 6.82% 13.84% 35.38%
Goodwill $2.061M $2.061M $2.061M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $70.00K $70.00K $70.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $4.120M $4.119M $3.523M
YoY Change 0.03% 24.41% 11.54%
TOTAL ASSETS
Total Short-Term Assets $9.581M $24.77M $14.87M
Total Long-Term Assets $4.120M $4.119M $3.523M
Total Assets $13.70M $28.89M $18.39M
YoY Change -52.58% 14.44% -36.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $760.0K $700.0K $650.0K
YoY Change 8.57% -14.63% -23.53%
Accrued Expenses $1.200M $830.0K $1.170M
YoY Change 44.58% 97.62% 21.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.378M $3.563M $2.910M
YoY Change -5.2%
Total Short-Term Liabilities $5.335M $5.099M $4.733M
YoY Change 4.61% 309.58% 160.65%
LONG-TERM LIABILITIES
Long-Term Debt $3.378M $4.280M
YoY Change -51.77% -38.34%
Other Long-Term Liabilities $321.6K $449.1K $84.28K
YoY Change -28.39% 227.85% -40.52%
Total Long-Term Liabilities $321.6K $3.827M $4.365M
YoY Change -91.6% -46.4% -38.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.335M $5.099M $4.733M
Total Long-Term Liabilities $321.6K $3.827M $4.365M
Total Liabilities $10.68M $19.68M $11.94M
YoY Change -45.73% 28.26% -50.71%
SHAREHOLDERS EQUITY
Retained Earnings -$85.44M -$77.29M -$66.44M
YoY Change 10.54% 23.96% -1.33%
Common Stock $74.80M $72.84M $72.88M
YoY Change 2.69% 0.81% 1.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.64M -$4.454M $6.444M
YoY Change
Total Liabilities & Shareholders Equity $13.70M $28.89M $18.39M
YoY Change -52.58% 14.44% -36.26%

Cashflow Statement

Concept 2020 Q1 2019 Q1 2018 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 plxp Beneficial Conversion Feature And Dividends Of Preferred Stock
BeneficialConversionFeatureAndDividendsOfPreferredStock
320290
CY2019Q1 plxp Beneficial Conversion Feature And Dividends Of Preferred Stock
BeneficialConversionFeatureAndDividendsOfPreferredStock
12820526
CY2020Q1 plxp Dividends Payable Noncurrent
DividendsPayableNoncurrent
1378788
CY2020Q1 plxp Accrued Bonuses And Severances Current
AccruedBonusesAndSeverancesCurrent
317634
CY2019Q4 plxp Accrued Bonuses And Severances Current
AccruedBonusesAndSeverancesCurrent
1166821
CY2019Q1 plxp Adjustments To Additional Paid In Capital Preferred Stock Beneficial Conversion Feature At Issuance
AdjustmentsToAdditionalPaidInCapitalPreferredStockBeneficialConversionFeatureAtIssuance
12692308
CY2019Q1 plxp Adjustments To Additional Paid In Capital Preferred Stock Beneficial Conversion Feature Deemed Dividend
AdjustmentsToAdditionalPaidInCapitalPreferredStockBeneficialConversionFeatureDeemedDividend
-12692308
CY2019Q4 plxp Dividends Payable Noncurrent
DividendsPayableNoncurrent
1058498
CY2020Q1 plxp Increase Decrease In Bonuses And Severances
IncreaseDecreaseInBonusesAndSeverances
-849187
CY2019Q1 plxp Increase Decrease In Bonuses And Severances
IncreaseDecreaseInBonusesAndSeverances
-574596
CY2020Q1 plxp Increase Decrease In Interest Payable Net Excluding Related Parties
IncreaseDecreaseInInterestPayableNetExcludingRelatedParties
20853
CY2019Q1 plxp Increase Decrease In Interest Payable Net Excluding Related Parties
IncreaseDecreaseInInterestPayableNetExcludingRelatedParties
54351
CY2020Q1 plxp Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-70069
CY2019Q1 plxp Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
CY2020Q1 plxp Interest Payable Noncurrent
InterestPayableNoncurrent
CY2019Q4 plxp Interest Payable Noncurrent
InterestPayableNoncurrent
501826
CY2020Q1 plxp Lessee Operating Lease Number Of Leases
LesseeOperatingLeaseNumberOfLeases
5
CY2020Q1 plxp Net Income Loss Available To Common Stockholders Before Impact Of Preferred Stock Participation Rights
NetIncomeLossAvailableToCommonStockholdersBeforeImpactOfPreferredStockParticipationRights
1175796
CY2019Q1 plxp Net Income Loss Available To Common Stockholders Before Impact Of Preferred Stock Participation Rights
NetIncomeLossAvailableToCommonStockholdersBeforeImpactOfPreferredStockParticipationRights
-23679277
CY2020Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
761588
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
928921
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
74789293
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
74837046
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
320290
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
128218
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
272537
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
66232
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
34969
CY2019Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
63375
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11155767
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10365446
CY2020Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
44697
CY2020Q1 us-gaap Assets
Assets
13701309
CY2019Q4 us-gaap Assets
Assets
18502746
CY2020Q1 us-gaap Assets Current
AssetsCurrent
9581209
CY2019Q4 us-gaap Assets Current
AssetsCurrent
14283255
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9286571
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14001304
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14250267
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24318786
CY2020Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4714733
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10068519
CY2020Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
9300000
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.50
CY2017Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2646091
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9156260
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9156260
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9156260
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9156260
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
9156
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
9156
CY2020Q1 us-gaap Contract With Customer Asset Gross
ContractWithCustomerAssetGross
0
CY2019Q4 us-gaap Contract With Customer Asset Gross
ContractWithCustomerAssetGross
0
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2020Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
43518
CY2020Q1 us-gaap Deferred Costs Current
DeferredCostsCurrent
43518
CY2019Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
CY2020Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
73665
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
73665
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
31668
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
55569
CY2020Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3648426
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
8247679
CY2020Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2019Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.71
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.71
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y73D
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2700000
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4599253
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
7726935
CY2020Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2493251
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2244160
CY2020Q1 us-gaap Goodwill
Goodwill
2061022
CY2019Q4 us-gaap Goodwill
Goodwill
2061022
CY2020Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1496086
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10858751
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
145828
CY2019Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
294862
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
90006
CY2020Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
CY2019Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-210851
CY2019Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
81955
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-16160
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2275
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-72609
CY2019Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-5146
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-14671
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-114133
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
177136
CY2020Q1 us-gaap Interest Payable Current
InterestPayableCurrent
557643
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
34964
CY2020Q1 us-gaap Inventory Net
InventoryNet
0
CY2019Q4 us-gaap Inventory Net
InventoryNet
0
CY2020Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
500000
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
500000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
47303
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
82350
CY2020Q1 us-gaap Lease Cost
LeaseCost
25842
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
682073
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
30132
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
60264
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
60819
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
262850
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
268008
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
74856
CY2020Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
320290
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
955000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
955000
CY2020Q1 us-gaap Liabilities
Liabilities
10683359
CY2019Q4 us-gaap Liabilities
Liabilities
16933129
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13701309
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18502746
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5334555
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6093430
CY2020Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
3377855
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3658121
CY2020Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
622265
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-937500
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13349078
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2346
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6891
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3774887
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3273668
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1496086
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-10858751
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
696560
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
696560
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4500728
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7939447
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q1 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
3007165
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
3236864
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3004642
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2919304
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
87601
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
607217
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
548089
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
618158
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y255D
CY2020Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
87601
CY2019Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
90344
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
319835
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
304603
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
321590
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
409431
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2346
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6891
CY2020Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
320290
CY2019Q1 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
12820526
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
248597
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
263268
CY2020Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
992704
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13661578
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1437324
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1466646
CY2020Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
2523
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
18683
CY2020Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
937500
CY2019Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
312500
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
513914
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85442077
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86938163
CY2020Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2523
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
317560
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.35
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
8750
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
90.80
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
554000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
272537
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
66232
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1125147
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
91475
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1666797
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2212047
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.96
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.70
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.16
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
49860
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y58D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y80D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y273D
CY2020Q1 us-gaap Stock Issued1
StockIssued1
CY2019Q1 us-gaap Stock Issued1
StockIssued1
22500
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
22500
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-10643628
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12091961
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6444293
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-4453944
CY2020Q1 us-gaap Sublease Income
SubleaseIncome
61759
CY2020Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
479236
CY2020Q1 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
16378788
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
16058498
CY2020Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
45000
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
45000
CY2020Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
15000
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
15000
CY2020Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
15000
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
15000
CY2019Q1 us-gaap Temporary Equity Stock Issued During Period Value New Issues
TemporaryEquityStockIssuedDuringPeriodValueNewIssues
CY2020Q1 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
13661578
CY2019Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
13661578
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, determining the fair value of warrant liabilities and other financial instruments, stock-based compensation, contingent liabilities, the fair value and depreciable lives of long-lived tangible and intangible assets, and deferred taxes and the associated valuation allowance. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div>
CY2017Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P10Y
CY2019Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2020Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
60407
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9216667
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8750543
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9156260
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8750543

Files In Submission

Name View Source Status
0001437749-20-010864-index-headers.html Edgar Link pending
0001437749-20-010864-index.html Edgar Link pending
0001437749-20-010864.txt Edgar Link pending
0001437749-20-010864-xbrl.zip Edgar Link pending
ex_183961.htm Edgar Link pending
ex_183962.htm Edgar Link pending
ex_183963.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
plxp-20200331.xml Edgar Link completed
plxp-20200331.xsd Edgar Link pending
plxp-20200331_cal.xml Edgar Link unprocessable
plxp-20200331_def.xml Edgar Link unprocessable
plxp-20200331_lab.xml Edgar Link unprocessable
plxp-20200331_pre.xml Edgar Link unprocessable
plxp20200331_10q.htm Edgar Link pending
plxp20200331_10qimg001.jpg Edgar Link pending
plxp20200331_10qimg002.gif Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending